SpringWorks Therapeutics, Inc. (SWTX)
Jul 1, 2025 - SWTX was delisted (reason: acquired by Merck KGaA)
46.99
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025
SpringWorks Therapeutics Employees
SpringWorks Therapeutics had 368 employees as of December 31, 2024. The number of employees increased by 63 or 20.66% compared to the previous year.
Employees
368
Change (1Y)
63
Growth (1Y)
20.66%
Revenue / Employee
$596,929
Profits / Employee
-$690,035
Market Cap
3.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 368 | 63 | 20.66% |
| Dec 31, 2023 | 305 | 78 | 34.36% |
| Dec 31, 2022 | 227 | 51 | 28.98% |
| Dec 31, 2021 | 176 | 98 | 125.64% |
| Dec 31, 2020 | 78 | 22 | 39.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
SWTX News
- 8 days ago - European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 25 days ago - Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business - Business Wire
- 5 weeks ago - SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors - GlobeNewsWire
- 7 weeks ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Business Wire
- 2 months ago - SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 3 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc. - PRNewsWire
- 3 months ago - Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B - Investopedia
- 3 months ago - Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal - WSJ